
Dr. Paller discusses factors influencing AD chronicity and comorbidities, focusing on disease severity, early onset, heredity, multiple allergies, and urban living as important in evaluating AD’s lasting effects on children.

Dr Kwatra poses the question: How do we assess disease modification in PN, and can treating early stop tissue damage and worsening of systemic diseases associated with PN?
Prof Jean-David Bouaziz describes the multifaceted burden of atopic dermatitis, beyond what can be seen on the skin, at EADV 2025.

Join Sanofi and Regeneron for an educational symposium on type 2 inflammation processes underlying pediatric asthma, atopic dermatitis, and eosinophilic esophagitis.

Join Prof. Kathryn Peterson for an expert review on how different immune cells and inflammatory mediators contribute to the pathogenesis of EoE.

This infographic illustrates the clinical manifestations, pathophysiology and impact on patients of skin dyspigmentation in Prurigo Nodularis.
Learn about the role of type 2 inflammation in the burden and pathophysiology of mucus plugging in severe asthma
In this video from EADV 2025, Dr. Netchiporouk discusses the clinical features, diagnosis, and burden of CSU
Learn from Prof. Papadopoulou as she highlights challenges in identifying EoE in pediatric patients and the consequences of delayed diagnosis.

In this video soundbite from the EAACI 2025 symposium, Dr. Zuzana Diamant explains pathophysiological mechanisms underlying asthma and CRSwNP, and how type 2 inflammatory cytokines drive airway remodelling in patients with severe asthma. Additionally, patients with co-existing asthma and CRSwNP have a higher type 2 inflammatory burden than patients with asthma alone.

The March 2025 ADVENT symposium in Orlando, Florida brought together 4 dermatology experts to explore the evolving science of type 2 inflammation. Type 2 inflammation plays a central role in the pathophysiology of multiple dermatological diseases, driving chronic immune dysregulation that affects patients with atopic dermatitis (AD) prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP). Understanding the mechanisms behind type 2 inflammation is key to advancing care and improving patient quality of life.

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.